ArticleNature2025
Microbiota-driven antitumour immunity mediated by dendritic cell migration.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.Gut microbes · 2026Review
- Review
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- Association of probiotic use with nivolumab efficacy in gastric cancer patients on gastric acid suppressants.iScience · 2026Article
- Low-Dose Intestinal Irradiation Enhances the Efficacy and Prognosis of PD-1 Blockade in Metastatic Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- Review
- The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Molecular cancer · 2026Review
- Newly isolated human-derivediScience · 2026Article
- Combination of Tripterygium glycosides and Lactobacillus paracasei sensitises epithelial ovarian cancer to cisplatin via downregulating Keap1-Nrf2-GPX4 signalling pathway.Cellular & molecular biology letters · 2026Article
- Obesity and melanoma: unraveling the paradoxical survival benefit in immunotherapy.Cancer metastasis reviews · 2026Review
- Shaping death: how the microbiome regulates tumour cell demise and therapy response.Cancer metastasis reviews · 2026Review
- ModulatingJournal for immunotherapy of cancer · 2026Article
- Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy.Scientific reports · 2026Article
- Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer.Immune network · 2026Review
- Gut microecology empowers cancer immunotherapy: commensal microbiota-mediated mechanisms and translational prospects of PD-1/PD-L1 therapy.Cancer biology & medicine · 2026Review
- Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer.Cell reports. Medicine · 2026Article
- Gut microbiota and the colorectal cancer tumor microenvironment: From carcinogenic mechanisms to therapeutic opportunities.World journal of gastrointestinal oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Nina Yi-Tzu Lin *Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-8118-1960
Shota Fukuoka *Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Shohei Koyama *Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Daisuke MotookaDepartment of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Dieter M TourlousseMolecular Biosystems Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan.ORCID 0000-0002-5177-5215
Yuko ShigenoBenno Laboratory, RIKEN Baton Zone Program, RIKEN Cluster for Science Technology and Innovation Laboratory, Saitama, Japan.ORCID 0000-0003-4327-9913
Yuki MatsumotoDepartment of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Hiroyuki YamanoDepartment of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Kazutoshi MurotomiMolecular Biosystems Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan.
Hideyuki TamakiBiomanufacturing Process Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan.ORCID 0000-0001-9208-1247
Takuma IrieDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Eri SugiyamaDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Shogo KumagaiDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Kota ItahashiDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Tokiyoshi TanegashimaDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Kaori FujimakiDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Sachiko ItoDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-9313-7089
Mariko ShindoDepartment of Anatomy and Molecular Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takahiro TsujiDepartment of Anatomy and Molecular Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-5706-8300
Hiroaki WakeDepartment of Anatomy and Molecular Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-8543-4590
Keisuke WatanabeDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Yuka MaedaDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Riu YamashitaDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chiba, Japan.
Takao FujisawaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Motoo NomuraDepartment of Head and Neck Oncology and Innovative Treatment, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akihito KawazoeDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.ORCID 0000-0002-3023-2510
Toshihiko DoiDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.ORCID 0000-0003-2042-6829
Kohei ShitaraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.ORCID 0000-0001-5196-3630
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Yuji SekiguchiMolecular Biosystems Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan.
Shota NakamuraDepartment of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Yoshimi BennoBenno Laboratory, RIKEN Baton Zone Program, RIKEN Cluster for Science Technology and Innovation Laboratory, Saitama, Japan. benno828@bigm.or.jp.
Hiroyoshi NishikawaDivision of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan. hnishika@ncc.go.jp.ORCID 0000-0001-6563-9807
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota influence the antitumour efficacy of immune checkpoint blockade
Indexed as
Cell MovementDendritic CellsGastrointestinal MicrobiomeNeoplasmsAnimalsAntigens, CDCD8-Positive T-LymphocytesCell Line, TumorFecal Microbiota TransplantationFecesFemaleHumansImmune Checkpoint InhibitorsIntegrin alpha ChainsMaleMicealpha E integrinsAntigens, CDImmune Checkpoint InhibitorsIntegrin alpha ChainsProgrammed Cell Death 1 Receptor
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.